GeoVax Labs (NASDAQ:GOVX) Stock Rating Lowered by Wall Street Zen

GeoVax Labs (NASDAQ:GOVX) was downgraded by Wall Street Zen to a “strong sell” rating in a research report issued to clients and investors on Saturday.

Other equities research analysts have also recently issued reports about the stock. D. Boral Capital decreased their price objective on shares of GeoVax Labs from $225.00 to $150.00 and set a “buy” rating for the company in a report on Wednesday, November 19th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GeoVax Labs in a research report on Wednesday, October 8th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $187.50.

GeoVax Labs Stock Performance

NASDAQ:GOVX opened at $2.99 on Friday. The company has a market capitalization of $3.59 million, a P/E ratio of -0.08 and a beta of 3.67. The stock’s 50 day moving average price is $7.48 and its 200 day moving average price is $13.34. GeoVax Labs has a 52 week low of $2.61 and a 52 week high of $57.50.

GeoVax Labs (NASDAQ:GOVX) last posted its earnings results on Thursday, November 13th. The company reported ($7.75) EPS for the quarter, missing the consensus estimate of ($6.00) by ($1.75). GeoVax Labs had a negative return on equity of 489.67% and a negative net margin of 403.88%. As a group, sell-side analysts forecast that GeoVax Labs will post -4.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GeoVax Labs

A number of hedge funds have recently bought and sold shares of the company. Jane Street Group LLC acquired a new stake in shares of GeoVax Labs in the first quarter valued at about $27,000. Sabby Management LLC acquired a new stake in GeoVax Labs in the 3rd quarter valued at approximately $313,000. Armistice Capital LLC bought a new position in GeoVax Labs in the 3rd quarter worth approximately $253,000. Finally, Hudson Bay Capital Management LP bought a new position in GeoVax Labs in the 3rd quarter worth approximately $47,000. 6.09% of the stock is currently owned by institutional investors.

About GeoVax Labs

GeoVax Labs, Inc is a clinical-stage biotechnology company focused on the development of novel vaccines and immunotherapies against infectious diseases. Leveraging a proprietary Modified Vaccinia Ankara (MVA) viral vector platform, GeoVax aims to induce robust and durable immune responses by expressing virus-like particles (VLPs) in vaccinated individuals. The company’s pipeline encompasses vaccine candidates for HIV, Ebola, Lassa, Zika, MERS and emerging coronaviruses, reflecting a commitment to addressing high-priority global public health threats.

The cornerstone of GeoVax’s technology is its MVA-VLP platform, which combines the safety profile of a non-replicating poxvirus vector with the potent antigen presentation of VLPs.